BridgeBio is a biopharmaceutical company dedicated to developing transformative medicines for patients with genetic diseases and cancers that have identifiable genetic foundations. Established in 2015, BridgeBio has built a diverse portfolio of over 30 drug development programs spanning preclinical to late-stage phases across various therapeutic areas, including genetic dermatology, precision oncology, cardiology, and neurology, among others. The company aims to bridge the gap between groundbreaking genetic research and the delivery of effective treatments, with two approved therapies already in its repertoire. With offices in the U.S. and international locations, BridgeBio fosters a collaborative environment that emphasizes scientific excellence, patient-centric approaches, and rapid execution. Employees are encouraged to uphold values such as transparency, accountability, and a commitment to putting patients first, cultivating a culture that inspires innovation and drives progress in addressing unmet medical needs.